IPO registrations (S-1, F-1) · Registrants
Insight Molecular Diagnostics Inc.
- SEC CIK
- 1642380 · filings on EDGAR ↗
- Name on the registration
- Oncocyte Corp
- Former names
- OncoCyte Corp (2020–2025); Oncocyte Corp (2020–2025)
- Registration
- Form S-1, first filed 2016-09-26, last 2025-03-28; 2 initial registrations, 2 amendments
- Outcome
- Declared effective 2016-10-20
- Industry (SIC)
- In Vitro & In Vivo Diagnostic Substances 2835
- Incorporated in
- CA
- Business address
- 2 INTERNATIONAL PLAZA DR., SUITE 510, Nashville, TN 37217
- EIN
- 27-1041563
- Ticker
- IMDX (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Insight Molecular Diagnostics Inc. on the corporate pages
Offering terms
- Shares offered
- 10,606,632
- Listing
- Nasdaq under the symbol OCX
- Lead underwriters
- of Contents
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: INSIGHT MOLECULAR DIAGNOSTICS INC. EXACT (EIN (EXACT))
- Form D issuer: Oncocyte Corp EXACT (CIK (EXACT))
- SEC filer: Insight Molecular Diagnostics Inc. EXACT (CIK (EXACT))
Filings 14
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2016-09-26 | S-1 | S-1 (registration) | OncoCyte Corp | 0001140361-16-080748 ↗ |
| 2016-10-18 | S-1/A | S-1/A (amendment) | OncoCyte Corp | 0001140361-16-082989 ↗ |
| 2016-10-19 | S-1/A | S-1/A (amendment) | OncoCyte Corp | 0001140361-16-083078 ↗ |
| 2016-10-20 | EFFECT | EFFECT (declared effective) | OncoCyte Corp | 9999999995-16-006031 ↗ |
| 2017-10-16 | EFFECT | EFFECT (declared effective) | OncoCyte Corp | 9999999995-17-002693 ↗ |
| 2019-06-18 | EFFECT | EFFECT (declared effective) | OncoCyte Corp | 9999999995-19-001369 ↗ |
| 2020-08-20 | EFFECT | EFFECT (declared effective) | OncoCyte Corp | 9999999995-20-002210 ↗ |
| 2021-06-08 | EFFECT | EFFECT (declared effective) | OncoCyte Corp | 9999999995-21-002268 ↗ |
| 2021-07-29 | EFFECT | EFFECT (declared effective) | OncoCyte Corp | 9999999995-21-002985 ↗ |
| 2024-05-22 | EFFECT | EFFECT (declared effective) | Oncocyte Corp | 9999999995-24-001624 ↗ |
| 2024-08-07 | EFFECT | EFFECT (declared effective) | Oncocyte Corp | 9999999995-24-002469 ↗ |
| 2024-10-21 | EFFECT | EFFECT (declared effective) | Oncocyte Corp | 9999999995-24-003231 ↗ |
| 2025-03-28 | S-1 | S-1 (registration) | Oncocyte Corp | 0001641172-25-001331 ↗ |
| 2025-04-07 | EFFECT | EFFECT (declared effective) | Oncocyte Corp | 9999999995-25-001011 ↗ |
Prospectus pages read 1
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-28 | S-1 | registration statement | 10,606,632 | - | Nasdaq OCX | 1 | primary document; shares headline, cover names 1 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| ANNETT WILLIAM | Director,Officer | President and CEO | 6 | 2015–2019 | |
| KARFUNKEL GEORGE | TenPercentOwner | 1 | 2015 | ||
| Last Andrew J. | Director | 18 | 2015–2026 | ||
| MECHEM KRISTINE C. | Officer | VP of Marketing | 5 | 2015–2018 | |
| Arno Andrew | Director | 23 | 2015–2026 | ||
| BIOTIME INC | Other; TenPercentOwner | 4 | 2015–2020 | ||
| KINGSLEY ALFRED D | Director | 16 | 2015–2023 | ||
| MOHANTY ADITYA P. | Director | 3 | 2015–2019 | ||
| Redmond Cavan M. | Director | 11 | 2015–2022 | ||
| SKIBSTED RUSSELL | Officer | Chief Financial Officer | 1 | 2015 | |
| CHAPMAN KAREN B. | Officer | Vice President of Research | 2 | 2016 | |
| SEGALL JUDITH | Officer | Corporate Secretary | 1 | 2016 | |
| WEST MICHAEL D | Director | 2 | 2016 | ||
| BAILEY DON M | Director | 4 | 2016–2017 | ||
| Bradsher Neal C | TenPercentOwner | 21 | 2016–2026 | ||
| BROADWOOD CAPITAL INC | TenPercentOwner | 21 | 2016–2026 | ||
| BROADWOOD PARTNERS LP | TenPercentOwner | 21 | 2016–2026 | ||
| HESTERBERG LYNDAL K. | Officer | Chief Scientific Officer; CSO; Sr VP, Research & Development | 6 | 2016–2020 | |
| Levine Mitchell S | Officer | CFO; Chief Financial Officer | 19 | 2017–2022 | |
| ANDREWS RONALD ASBURY | Director; Director,Officer | CEO and President; Chief Executive Officer; Former CEO; President & CEO | 16 | 2018–2022 | |
| Parker Albert P | Officer | Chief Operating Officer; COO | 5 | 2018–2020 | |
| Sundar Padma | Officer | Chief Commercial Officer; SVP, Marketing & Market Access | 5 | 2019–2022 | |
| GRIFFITH MELINDA | Director | 5 | 2019–2022 | ||
| KALAJIAN TONY T | Officer | Sr.VP/Chief Accounting Officer; SVP, Chief Accounting Officer; SVP-Chief Accounting Officer | 4 | 2019–2020 | |
| Ross Douglas T. | Officer | Chief Medical Officer; Chief Scientific Officer; CMO; Former CSO; Former CSO. | 8 | 2020–2022 | |
| Carter Jennifer L. | Director | 4 | 2020–2022 | ||
| Kamen Efrem | TenPercentOwner | 9 | 2021–2023 | ||
| PURA VIDA INVESTMENTS, LLC | TenPercentOwner | 9 | 2021–2023 | ||
| Yu Li | Officer | VP Cntrllr/Prncpl Acctng Offcr | 4 | 2021–2022 | |
| Paulsen Gisela | Officer | Chief Operating Officer; Former President and COO; President & COO | 4 | 2021–2022 | |
| John Anish M. | Officer | Chief Financial Officer; SVP, Finance, and Interim CFO | 5 | 2022–2023 | |
| Gutfreund John Peter | Director; Other | 5 | 2022–2023 | ||
| Liu James Yang | Officer | Controller, PAO; Sr Dir., Cntlr, PAO, Int PFO; Sr Dir Controller PAO Int PFO; VP ACCT, Cntlr, Treasurer, PAO | 7 | 2022–2026 | |
| Riggs Josh | Director,Officer; Officer | CEO; CEO and President; Interim CEO | 10 | 2022–2026 | |
| SILVERMAN LOU | Director | 6 | 2022–2026 | ||
| James Andrea S. | Officer | Chief Financial Officer | 11 | 2024–2026 | |
| SMITH PATRICK W | TenPercentOwner | 6 | 2024–2025 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2025-02-24 | Oncocyte Corp | Biotechnology | $21,743,597 | $21,743,597 | 12 | 1 |
| 2024-10-08 | Oncocyte Corp | Biotechnology | $10,204,262 | $10,204,262 | 16 | 1 |
| 2024-04-25 | Oncocyte Corp | Biotechnology | $15,807,692 | $15,807,692 | 21 | 1 |
| 2021-04-29 | OncoCyte Corp | Biotechnology | $17,500,000 | $3,006,577 | 75 | 1 |
| 2021-03-08 | OncoCyte Corp | Biotechnology | $5,000,000 | $5,000,000 | 7 | 1 |
| 2020-02-11 | Oncocyte Corp | Biotechnology | $11,000,000 | $5,000,000 | 29 | 1 |
| 2016-09-09 | OncoCyte Corp | Biotechnology | $10,549,997 | $10,549,997 | 9 | 1 |
| 2015-10-15 | OncoCyte Corp | Biotechnology | $11,350,738 | $8,349,439 | 1 | 1 |
| 2015-05-14 | OncoCyte Corp | Biotechnology | $3,300,000 | $3,300,000 | 2 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | Oncocyte Corp | CA | Form D private offerings | CIK (EXACT) |
| SEC filer | Insight Molecular Diagnostics Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Form 5500 plan sponsor | INSIGHT MOLECULAR DIAGNOSTICS INC. | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry In Vitro & In Vivo Diagnostic Substances, TN first:
- Anbio Biotechnology 2M
- Asep Medical Holdings Inc. A1
- DNA Testing Centers Corp A6
- NYMOX PHARMACEUTICAL CORP A8
- MABCURE INC. B9
- ANSYS DIAGNOSTICS INC CA
- Monogram Biosciences, Inc. CA
- ARGONAUT TECHNOLOGIES INC CA
- GENENCOR INTERNATIONAL INC CA
- Intuity Medical, Inc. CA
In other datasets, the same topic (Health) in TN:
- Nonprofit: 2 MILLION DOGS 2 MILES INC (Nonprofits (IRS Form 990))
Interests: In Vitro & In Vivo Diagnostic Substances · Health